Neuronetics (STIM) CEO awarded 1,500,000 restricted stock units in equity grant

Rhea-AI Filing Summary

REUVERS DANIEL L. reported acquisition or exercise transactions in this Form 4 filing.

Neuronetics, Inc. President and CEO Daniel L. Reuvers reported an equity compensation award of 1,500,000 shares of common stock on March 23, 2026, coded as a grant. The award is structured as restricted stock units that vest in three equal annual installments beginning on March 23, 2027, subject to his continuous service. Each RSU gives a contingent right to receive one share of common stock, and following this award he reports 1,500,000 shares/units held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider REUVERS DANIEL L.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,500,000	$0.00	--

Holdings After Transaction: Common Stock — 1,500,000 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on March 23, 2027, in each case subject to continuous service of the Reporting Person through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REUVERS DANIEL L.

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		A		1,500,000(1)	A	$0(2)	1,500,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on March 23, 2027, in each case subject to continuous service of the Reporting Person through such date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Patrick Devine, as Attorney-in-Fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neuronetics (STIM) disclose for its CEO?

Neuronetics disclosed that President and CEO Daniel L. Reuvers received a grant of 1,500,000 shares on March 23, 2026. The award is reported as a restricted stock unit grant under Form 4, rather than an open-market stock purchase or sale.

How many RSUs did the Neuronetics (STIM) CEO receive and when do they vest?

The CEO received 1,500,000 restricted stock units that vest in three equal annual installments. Vesting begins on March 23, 2027, with additional installments each year thereafter, and remains conditioned on his continuous service with Neuronetics through each vesting date.

Is the Neuronetics (STIM) CEO’s Form 4 a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market purchase. The 1,500,000 units are reported with transaction code “A” for a grant or award, at a price per share of 0.0000, indicating an equity award rather than a cash-funded transaction.

What does each RSU in the Neuronetics (STIM) CEO’s grant represent?

Each restricted stock unit represents a contingent right to receive one share of Neuronetics common stock. Delivery of the underlying shares depends on the RSUs vesting as scheduled and Daniel L. Reuvers continuing his service with the company through each vesting date.

What are Daniel L. Reuvers’ reported holdings after this Neuronetics (STIM) grant?

After the reported grant, Daniel L. Reuvers shows 1,500,000 shares or units of Neuronetics common stock as directly held. This figure comes from the Form 4 field indicating total shares following the transaction for the reported non-derivative equity award.